1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Brent Saunders Plots Return To Deal-Making With A SPAC IPO

 
• By Mandy Jackson

Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.

Finance Watch

The question of where former Allergan plc CEO Brent Saunders would land next after the company was sold to AbbVie Inc. earlier this year for $63bn was answered in a 10 September filing with the US Securities and Exchange Commission (SEC) by Vesper Healthcare Acquisition Corp., which said it wants to raise up to $460m in a forthcoming initial public offering to buy pharmaceutical companies in market niches where the executive has a history of making deals.

Miami Beach, FL-based Vesper is a special purpose acquisition corporation (SPAC) and Saunders is its chairman, CEO and president. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.